/** Title: Narayana Health Q1 FY27: India execution stands out as UK and insurance remain works in progress */

Narayana Health Q1 FY27: India execution stands out as UK and insurance remain works in progress

Narayana Hrudayalaya Limited reported a sharp jump in consolidated operating revenue in Q1 FY27, helped by the addition of the UK business and steady momentum in India. For the quarter ended June 30, 2026, consolidated operating revenue rose to Rs 2,683.6 crore from Rs 1,507.3 crore in Q1 FY26. Consolidated EBITDA increased to Rs 505.2 crore, with an 18.8% margin, while PAT stood at Rs 207.3 crore.

The quarter was also a reminder that Narayana Health is now a more complex story. India hospitals are delivering strong throughput-led margin expansion without meaningful bed additions, while the international portfolio is still settling into a steady rhythm. Alongside, the integrated care approach, clinics plus insurance, is building engagement but continues to dilute reported profitability in the near term.

India hospitals: a combination of volumes and realizations

India operations revenue for Q1 FY27 was Rs 1,319.6 crore, up 16.6% year on year. Management highlighted a mix of high-end procedures, including wider adoption of robotic surgery, and stronger referral visibility through clinics as reasons for the improved momentum in both realizations and volumes.

Operational metrics point to healthy throughput. Hospital outpatient footfalls increased to 674,000 in Q1 FY27 from 617,000 in Q1 FY26, while inpatient discharges rose to 57,000 from 53,000. ICU occupied bed days also improved to 96,000 from 85,000.

Realizations were stable to modestly higher. Average revenue per OP patient moved to Rs 5.1k from Rs 4.8k. For IP, it was Rs 163k versus Rs 149k in the prior year. ALOS remained at 4.3 days. On the call, Dr. Emmanuel Rupert stated that the intention is to bring ALOS down to a 3.9 to 4.0 range over time, while acknowledging that complex case-mix can influence the glide path.

Profitability remains the key differentiator. India Hospitals EBITDA margin expanded to 24.8% in Q1 FY27 from 19.2% in Q1 FY26. Cost structure percentages were largely stable quarter-on-quarter, with doctors and nurses at 28% of operating revenues, consumables at 23%, other expenses at 17%, and other manpower at 10%.

The revenue mix disclosed for India hospitals shows the model Narayana Health continues to execute. Owned hospitals contributed 73% of operating revenue, operated hospitals 25%, and heart centres 1% (excluding NHIC). In specialty terms, cardiac sciences remained the largest at 33%, followed by oncology at 16% and medicine plus GI sciences at 13%. Payor mix continues to lean on domestic walk-ins at 43%, insured patients at 33%, and schemes at 18%, with international patients at 5%.

International portfolio: Cayman steady in volumes, UK sees disruption

Cayman hospital revenues were US$44.8 million in Q1 FY27, up 5.1$ -3.7 million, reflecting ongoing profitability pressure at the Cayman entity level in this quarter.

Cayman insurance revenues (CIHL) were US$15.4 million in Q1 FY27, up sharply year on year. On the call, management indicated that renewals repriced from July saw 100% acceptance, and that the benefit of repricing would begin reflecting in Q2 results.

In the UK, Q1 FY27 hospital revenues were GBP 65.0 million, down 3.8% QoQ from GBP 67.6 million in Q4 FY26. EBITDA post-IFRS was GBP 5.7 million (8.8% margin), down from GBP 7.1 million (10.5% margin) in Q4 FY26. Management attributed the quarter’s weakness largely to a severe heat wave that disrupted critical infrastructure and led to operational downtime due to HVAC failures, an issue that can materially impact a business starting from a low-margin base.

Management also provided additional color on its UK transformation thesis. The acquired business was about 95% NHS at acquisition. Management referenced peer mixes closer to 70% NHS as a directional target, with an expected 4 to 5 year journey to move payor mix. Early progress was described as encouraging, with the private contribution at a historical high for the acquired business, though the company did not share an updated private versus NHS split.

Integrated care: clinics show traction, insurance remains volatile

Integrated care is emerging as a strategic pillar that management believes can improve engagement, strengthen referrals, and over time support more informed underwriting at a portfolio level. The clinic business, particularly around Bengaluru, was described as a meaningful contributor to footfall and conversion into complex procedures at flagship hospitals.

Clinic transaction metrics were cited on the call. The company reported about 66,000 consultations across the clinic network during the quarter, and stated that OP consults have grown about 30% year on year.

However, profitability remains a near-term drag. Management referenced approximately Rs 15 crore loss for the India clinic business in Q1 FY27.

The insurance business in India continues to be the biggest swing factor. Gross written premium increased to Rs 26.2 crore in Q1 FY27 from Rs 1.7 crore in Q1 FY26, but underwriting performance deteriorated sharply in the quarter. PAT was Rs -20.1 crore in Q1 FY27. The claims ratio to net earned premium was 219% and the combined operating ratio was 259%. Management described the book as small and therefore volatile, where a few large claims can disproportionately affect ratios.

Mitigation actions were laid out in qualitative terms. These include implementing AI solutions to review claims and minimize fraud, waste and abuse, increasing in-house claims processing, and sharpening audits with partners such as TPAs. Management also stated that growth focus remains on SME and retail segments, which it characterized as having better margins than large group medical cover accounts.

Balance sheet and capex: cash build and a multi-year bed addition pipeline

Narayana Health ended the quarter with a sizeable liquidity buffer. As of June 30, 2026, cash and bank balance stood at Rs 1,993.4 crore and current investments were Rs 824.0 crore. Shareholder equity was Rs 4,733.6 crore.

Net borrowings remain meaningful. Total borrowings were Rs 4,877.6 crore, with lease liabilities of Rs 971.1 crore. The investor presentation also highlighted that consolidated total borrowings less cash, bank balance and investments were Rs 1,967.1 crore, translating to a net debt to equity ratio of 0.42. The company also disclosed foreign currency denominated debt of US$115 million and GBP150 million.

Management’s stance on capital allocation is clear in direction even if not quantified into return metrics. Cash is expected to be deployed into the expansion program, and on the call the CFO referenced about Rs 3,000 crore of committed projects over the next two years, to be funded through a mix of internal accruals and borrowings.

The capex table in the presentation outlines a bed capacity build-out with project-level detail. Key projects include:

HSR, Bangalore: 215 beds, project cost Rs 490 crore, targeted completion FY28 Rajarhat, Kolkata: 350 beds, project cost Rs 900 crore, targeted completion FY29 (timelines shifted) Central Bangalore (lease): 220 beds, project cost Rs 160 crore, targeted completion FY29 (timelines shifted) South Bangalore: 350 beds, project cost Rs 800 crore, targeted completion FY30 (timelines shifted) Raipur expansion: 300 beds, project cost Rs 540 crore, targeted completion FY28 South-West Bangalore (lease): 100 beds, project cost Rs 84 crore, targeted completion FY27

Management acknowledged that some asset-light partner model projects have faced delays due to licensing issues on the partner side, and indicated these are expected to be addressed.

Financial summary (Q1 FY27)

Note: India operations revenue in the presentation is stated as excluding ATHMA and Medha and adjusted for inter-company eliminations.

Takeaways

Q1 FY27 underscores a split narrative. The India hospital business continues to demonstrate operating leverage, with margin expansion supported by higher-end procedures and improving throughput metrics. At the same time, the newer layers of the group, India insurance and the UK acquisition, add volatility and execution requirements.

The expansion pipeline is large and clearly articulated, backed by a strong cash position. Over the next few years, delivery against timelines, progress on UK payor mix diversification, and stabilization of insurance loss ratios are likely to determine how smoothly the company translates its operating momentum into a more consistent consolidated margin profile.